Health Trials

Air Pollution and Cardiovascular Disease in Qatar: an Interventional Study to Reduce Blood Pressure

ConditionsHypertension, SystolicMetabolic Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorWeill Cornell Medical College in Qatar

About this trial

The main objective is to determine if in-home portable air cleaners provide persistent reductions in PM2.5 exposures and improvements in systolic blood pressure and biochemical parameters over 4-weeks in patients with metabolic syndrome residing in Qatar.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Non-smokers (100% abstinence from use of any smoking or vaping product during the prior year)

Age ≥18 and less than 60 years old

Living in a single residence (home, apartment) located anywhere in Qatar

Waist circumference ≥102 cm if male and ≥88 cm if female

Disqualifiers

Pregnancy (self-reported)

Screening visit urine positive for cotinine (NicAlert >100 ng/mL)

Living with an active smoker who smokes indoors (by self-report)

High risk conditions that prohibit allowing home BP to be >130/80 mm Hg during the10-week trial including any cardiovascular disease (coronary artery disease, prior stroke, heart failure, peripheral arterial disease, aneurysm) or ≥ stage 3 kidney disease (estimated glomerular filtration rate < 60 ml/min)

Trial design

Design model

Crossover

Treatments tested in this trial

  • Air cleaners with HEPA filter

    Device

    PM 2.5 exposure reduction using in home portable air cleaners fitted with HEPA filters

  • Air cleaners without HEPA filter

    Device

    Simulation of PM 2.5 exposure reduction using in home portable air cleaners without HEPA filters.

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Active modeActive comparator 1 intervention
Group B: Sham modeSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in Systolic Blood Pressure

Mean change from baseline in systolic blood pressure

Time frame
week 4, week 10

Secondary outcomes

1

Change in Fasting Glycemia

Mean change from baseline in fasting glycemia

Time frame
week 4, week 10
2

Change in Insulin Resistance Index

Mean change from baseline in Insulin Resistance Index

Time frame
week 4, week 10

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weill Cornell Medical College in Qatar

Lead sponsor

Hamad Medical Corporation

Collaborator

Case Western Reserve University

Collaborator

Source ClinicalTrials.gov
Apply now